A study concentrating on the use of magic mushrooms in Canada revealed that nearly 80% of participants expressed their conviction that psilocybin should be medically accessible for patients experiencing distress. Moreover, about two-thirds of the Canadian respondents in the same study concurred that psilocybin should be legally obtainable for those in need.
Besides advocating for easier availability of the substance, a notable 84.8 percent of participants opined that the public health system should cover the expenses of such treatments. A majority of Canadians regard psilocybin as an effective alternative, particularly for alleviating end-of-life distress.
[toc]
Main Findings:
- Residents of Québec, Ontario, Alberta, and British Columbia view psilocybin as an effective medical option for treating end-of-life existential distress.
- Magic mushrooms are regarded as safe for addressing existential distress.
- Participants in two double-blind trials reported instant and long-lasting benefits, with effects enduring six months or more.
A Closer Look at Existential Distress
Existential distress, akin to existential suffering, spiritual distress, and demoralization, arises when individuals grapple with their mortality. This distress can evoke feelings of helplessness, isolation, anxiety, and a sense of lost purpose and meaning. Especially among patients with life-threatening diseases, it can potentially catalyze a wish to hasten death or ponder suicide.
Typically, those dealing with terminal diseases or significant life changes are the most susceptible to this form of distress. It significantly impacts their psychological health and overall life quality.
Existential therapy aims to tackle issues such as anxiety, depression, grief, loneliness, apathy, despair, identity confusion, and feelings of aimlessness and existential fear. It often involves multiple sessions and may not be beneficial for everyone.
The ambiguity around the effectiveness of this therapy is a prime motivation for many individuals to seek alternative treatments.
Health Canada’s Stance on Psilocybin for Treatment
Over the last two decades, preliminary clinical trials have highlighted the potential advantages of psychedelic substances in the treatment of complex mental disorders. Psilocybin, in particular, has demonstrated the ability to rapidly and persistently alleviate existential distress in patients nearing life’s end.
Recognizing the potential efficacy of such hallucinogenic mushrooms, especially when traditional treatments fail, Health Canada revised the Special Access Program in 2022. This revision enables healthcare professionals to request controlled substances for their patients.
Canadian Support for Psilocybin Access
A study published in the Palliative Care Journal evaluates societal views on psilocybin-assisted therapy for end-of-life care. The data from the study include:
| Methodology | Participation from 2,800 Canadians from Québec, Ontario, Alberta, and British Columbia. 19% of whom had previously used psilocybin (15% in Québec, 26% in British Columbia). |
| Findings | 79.3% view psilocybin-assisted therapy as a valid medical option for treating end-of-life existential distress. 63.3% believe psilocybin should be integrated into medical treatment. 84.8% support the delivery of this therapy by the public health system. 44.2% believe healthcare professionals should administer the substance without Health Canada’s supervision. |
The findings are in line with surveys conducted in Canada, England, and Australia. The researchers highlighted that their study is unique because it focuses on the use of psychoactive substances to manage existential distress in end-of-life situations.
Why Canadians Support Psilocybin Use
An increasing number of Canadians are acknowledging the benefits of psilocybin as a treatment, mainly due to evidence from reputable research institutions. Another factor contributing to this acceptance is the perceived safety of psilocybin mushrooms in reducing existential distress. Participants in various studies have not reported severe adverse health outcomes, such as multi-organ failure.
| Study | Approach | Results |
| Johns Hopkins Study | 51 patients were administered a high dose of psilocybin and a low dose as an active placebo control | Immediate and prolonged The benefits can last up to six months or even longer. The effectiveness of the therapy is mainly due to mystical experiences that involve a sense of unity and deeply impactful emotional insights. |
| Trial at New York University | 29 patients were randomly selected to receive either psilocybin or the active placebo known as niacin | The results were in line with those from the Johns Hopkins study. Participants who received psilocybin reported psychological relief and a more positive outlook on life and death. |
| BMC Palliative Care | Interviews were conducted with nineteen participants, including 7 doctors, 4 nurses, 4 chaplains, 3 social workers, and a psychologist. The aim of the study was to understand how palliative care professionals perceive existential distress and their opinions on psychedelic therapy as a potential treatment. | Palliative care practitioners suggested that psychedelic-assisted therapy (PAT) may be effective in reducing existential distress. |
Patient Experiences
Scientific studies are not the only evidence supporting the effectiveness of psilocybin. Several narratives from patients also highlight its potential to improve mental wellbeing and overall quality of life.
The Journey of Yokoi
Mio Yokoi, who was diagnosed with terminal stage 4 pancreatic cancer, shares a transformative experience from her assisted therapy. She visualizes herself on a raft, surrounded by nature and colourful creatures. This vision gives her a profound understanding of the universe’s interconnectedness and support, which brings her immense comfort and validation.
Despite receiving conventional mental health support, Yokoi continued to struggle with severe anxiety and distress after her diagnosis. Psilocybin therapy helped her reconnect with her body and provided a tangible sense of love and support. This significantly improved her emotional and mental health.
Chrissy’s Narrative
Chrissy, a woman in her 50s, was diagnosed with stage 4 breast cancer that had metastasized to her lungs. She was working full-time as an administrative supervisor in healthcare when the study took place and identified herself as an atheist. She was diagnosed with Generalized Anxiety Disorder during her screening.
Chrissy reported significant reductions in her levels of anxiety, depression, fear of death, hopelessness, and demoralization. When asked about any changes in her religious or spiritual beliefs since her therapy session, she stated that the experiences had brought a sense of purpose and authenticity to her beliefs.
Brenda’s Journey
In her therapy sessions, Brenda confronted death twice. These encounters left her with no fear of death, instead seeing it as a beautiful part of life’s journey. She credited the study for her healing from childhood trauma, a transformation reflected in her data. Significant improvements in anxiety and death-related fears, accompanied by increased spirituality, were observed.
Availability of Magic Mushroom Products in Canada
At present, there may be restrictions on the availability of psilocybin capsules and other products intended to alleviate existential distress or other mental health conditions. Nevertheless, reliable online dispensaries can serve as a valuable source for these products as needed.
| Features | Brazilian Psilocybe Cubensis | Cambodian Psilocybe Cubensis | Melmac Psilocybe Cubensis |
| Origin | Originates in Brazil and some neighboring South American countries. | Discovered in Cambodia, particularly around the Angkor Wat Temple. | Associated with Penis Envy mushrooms, which became popular in the 1970s. |
| Potency | Moderately potent; suitable for beginners. | Also moderately potent; ideal for those new to the experience. | Extremely potent; recommended for individuals with intermediate to advanced exposure. |
| Effects | Causes mental stimulation, slight confusion, enhanced color perception, euphoria, spiritual experiences, boosted creativity, and improved concentration. | Triggers an invigorating and lasting high, minor visual changes, increased creativity, euphoria, a gentle physical high, fractal imagery, and feelings of joy. | Instigates deep shamanic experiences, vision quests, intense mystical experiences, increased creativity, concentration, social awareness, and mood improvement. |
Ease End-of-life Discomfort with Psilocybin Products
The existential distress or discomfort experienced at the end of life can be a significant burden for many patients. Traditional treatments may not always effectively address this distress, leading to a surge in Canadian support for more accessible magic mushrooms within public healthcare. This growing public interest could We urge regulatory authorities to regard magic mushrooms as a potential alternative treatment option. Obtain your psychedelics and mushroom delivery from Shrooms Online Canada.
Frequently Asked Questions
What should patients expect during Psilocybin-Assisted Therapy?
Psychedelic-assisted therapy (PAT) experiences can differ greatly among patients, and meticulous preparation alongside careful adherence to certain procedures is crucial for a positive outcome. Patients must undergo thorough screening and mental readiness prior to substance intake.
- Pre-Session Preparation: Patients undergo a comprehensive assessment. The therapist discusses the patient’s goals and expectations to set intentions for the session. The effects and potential experiences during the session are explained to the patient by the therapist.
- The Session: A controlled dose of the substance is given to patients in a serene, distraction-free environment to foster relaxation and introspection. Throughout this, continuous support and guidance are provided by the therapist.
- Post-Session Integration Therapy: This therapy assists the patient in comprehending and assimilating their experiences. The following sessions provide ongoing support and counselling to reinforce the insights and changes achieved during therapy.
How does psilocybin affect the brains of distressed patients?
It interacts with the brain by binding to serotonin receptors, predominantly the 5-HT2A receptor. This interaction can induce alterations in perception, mood, and cognition, leading to substantial shifts in consciousness, emotional disclosures, and novel perspectives.
Is psilocybin therapy available to everyone?
Psilocybin therapy isn’t appropriate for everyone. Patients suffering from certain mental health conditions or existential distress are thoroughly screened to eliminate those with a history of psychosis.
Related Articles:
